Japanese-based Eisai has announced the licensing of Fycompa (perampanel) for adjunctive treatment of partial-onset seizures in Jordan, Saudi Arabia and the United Arab Emirates (UAE).

Fycompa can be used to treat the seizures with or without secondarily generalised seizures, and is also indicated in the UAE to treat primary-generalised, tonic-clonic seizures in patients with idiopathic generalised epilepsy (IGE) aged 12 and older.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Eisai has partnered with Hikma Pharmaceuticals to make Fycompa available in these countries.

The drug targets a type of receptor that plays a critical role in the onset and spread of seizures.

Kork Epilepsy Centre professor, medical director and executive chief physician Bernhard Steinhoff said: "Many patients need multiple anti-epileptic drugs to achieve optimal seizure control.

See Also:

"The availability of a new treatment option will be welcomed by healthcare professionals and by people living with epilepsy alike."

“The availability of a new treatment option will be welcomed by healthcare professionals and by people living with epilepsy alike."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Fycompa is a non-competitive, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), glutamate receptor antagonist on post-synaptic neurons.

Eisai EMEA global neurology business group vice-president Neil West said: "Eisai is committed to the therapeutic area of neurology and to addressing the unmet medical needs of people with neurological conditions and their families.

“Ensuring access for patients to novel treatments underlines Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide."

AMPA receptors are present in almost all excitatory neurons and transmit signals stimulated by the excitatory neurotransmitter glutamate within the brain.

They also play a vital role in central nervous system diseases that are characterised by excess neuroexcitatory signalling, including epilepsy.